Molecular analysis of neurotransmitter transport into secretory vesicles

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 61, Issue , 1996, Pages 747-758

  Liu, Y ^a   Waites, C ^a   Krantz, D ^a   Tan, P ^a   Edwards, R H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; CARRIER PROTEIN; GLUTAMIC ACID; NEUROTRANSMITTER; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; NEUROTRANSMITTER TRANSPORTER;

ANIMAL CELL; CELL MEMBRANE TRANSPORT; CHO CELL; CHROMOSOME 10Q; CHROMOSOME 8P; CONFERENCE PAPER; MEMBRANE VESICLE; MOLECULAR CLONING; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; ACTIVE TRANSPORT; AMINE TRANSPORT; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CELL POPULATION; CHO CELL LINE; DNA LIBRARY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EXOCYTOSIS; HUMAN; NEUROTRANSMISSION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; RESPIRATORY CHAIN; SECRETORY VESICLE; SUBSTANTIA NIGRA; SYMPATHETIC GANGLION;

ANIMALIA;

EID: 0030427643     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.1996.061.01.074     Document Type: Conference Paper

References (113)

1. Alfonso, A., K. Grundahl, J.S. Duerr, H.-P. Han, and J.B. Rand. 1993. The Caenorhabditis elegans unc-17 gene: A putative vesicular acetylcholine transporter. Science 261: 617.
2. Alfonso, A., K. Grundahl, J.R. McManus, J.M. Asbury, and J.B. Rand. 1994. Alternative splicing leads to two cholinergic proteins in Caenorhabditis elegans. J. Mol. Biol. 241: 627.
3. Amara, S.G. and M.J. Kuhar. 1993. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16: 73.
4. Anderson, D.C., S.C. King, and S.M. Parsons. 1982. Proton gradient linkage to active uptake of 3H-acetylcholine by Torpedo electric organ synaptic vesicles. Biochemistry 21: 3037.
5. Bahr, B.A. and S.M. Parsons. 1992. Purification of the vesamicol receptor. Biochemistry 31: 5763.
6. Bejanin, S., R. Cervini, J. Mallet, and S. Berrard. 1994. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem. 269: 21944.
7. Bennett, M.K. and R.H. Scheller. 1994. A molecular description of synaptic vesicle membrane trafficking. Annu. Rev. Biochem. 63: 63.
8. Berse, B. and J.K. Blusztajn. 1995. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J. Biol. Chem. 270: 22101.
9. Betz, W.J. and G.S. Bewick. 1992. Optical analysis of synaptic vesicle cycling at the frog neuromuscular junction. Science 255: 200.
10. Carboni, E., A. Imperato, L. Perezzani, and G.D. Chiara. 1989. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the rat nucleus accumbens of freely moving rats. Neuroscience 28: 653.
11. Carlsson, A. 1965. Drugs which block the storage of 5-hydroxytryptamine and related amines. Handb. Exp. Pharmacol. 19: 529.
12. Choi, D.W. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623.
13. Cohen, G. 1990. Monamine oxidase and oxidative stress at dopaminergic synapses. J. Neural Transm. Suppl. 32: 229.
14. Cubells, J.F., S. Rayport, G. Rajendran, and D. Sulzer. 1994. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14: 2260.
15. Daniels, A.J. and J.F. Reinhard. 1988. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J. Biol. Chem. 263: 5034.
16. Darchen, F., E. Scherman, and J.P. Henry. 1989. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry 28: 1692.
17. Denton, T. and B.D. Howard. 1987. A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurochem. 49: 622.
18. Desnos, C., M. Laran, and D. Scherman. 1992. Regulation of the chromaffin granule catecholamine transporter in cultured bovine adrenal medullary cells-stimulus biosynthesis coupling. J. Neurochem. 59: 2105.
19. Desnos, C., B. Raynaud, S. Vidal, M.J. Weber, and D. Scherman. 1990. Induction of the vesicular monoamine transporter by elevated potassium concentration in cultures of rat sympathetic neurons. Dev. Brain Res. 52: 161.
20. Deutch, A.Y., J.D. Elsworth, M. Goldstein, K. Fuxe, D.E. Redmond, J.R. Sladek, and R.H. Roth. 1986. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 68: 51.
21. Di Chiara, G. and A. Imperato. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. 85: 5274.
22. Edwards, R.H. 1992. The transport of neurotransmitters into synaptic vesicles. Curr. Opin. Neurobiol. 2: 586.
23. Eldridge, R. and W.A. Rocca. 1992. Parkinson's disease. In The genetic basis of common diseases vol. 20, p. 775. Oxford University Press, New York.
24. Erickson, J.D. and L.E. Eiden. 1993. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. J. Neurochem. 61: 2314.
25. Erickson, J.D., L.E. Eiden, and B.J. Hoffman. 1992. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. 89: 10993.
26. Erickson, J.D., H. Varoqui, M.D. Schafer, W. Modi, M.F. Diebler, E. Weihe, J. Rand, L.E. Eiden, T.I. Bonner, and T.B. Usdin. 1994. Functional identification of a vesicular acetylcholine transporter and its expression from a "cholinergic" gene locus. J. Biol. Chem. 269: 21929.
27. Fahn, S. and G. Cohen. 1992. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32: 804.
28. Farquhar, M.G., J.J. Reid, and L.W. Daniell. 1978. Intracellular transport and packaging of prolactin: A quantitative electron microscope autoradiographic study of mamotrophs dissociated from rat pituitaries. Endocrinology 102: 296.
29. Fisher, J.F. and A.K. Cho. 1979. Chemical release of DA from striatal homogenates: Evidence for an exchange diffusion model. J. Pharmacol Exp. Ther. 268: 203.
30. Floor, E., P.S. Leventhal, Y. Wang, L. Meng, and W. Chen. 1995. Dynamic storage of dopamine in rat brain synaptic vesicles in vitro. J. Neurochem. 64: 689.
31. German, D.C., K.F. Manaye, P.K. Sonsalla, and B.A. Brooks. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann. N.Y. Acad. Sci. 648: 42.
32. Gilmor, M.L., N.R. Nash, A. Roghani, R.H. Edwards, H. Yi, S.M. Hersch, and A.I. Levey. 1996. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J. Neurosci. 16: 2179.
33. Heeringa, M.J. and E.D. Abercrombie. 1995. Biochemistry of somatodendritic dopamine release in substantia nigra: An in vivo comparison with striatal dopamine release. J. Neurochem. 65: 192.
34. Heikkila, R.E., L. Manzino, F.S. Cabbat, and R.C. Duvoisin. 1984. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467.
35. Hernandez, L., F. Lee, and B.G. Hoebel. 1988. Microdialysis in the nucleus accumbens during feeding on drugs of abuse: Amphetamine, cocaine and phencyclidine. Ann. N. Y Acad. Sci. 537: 508.
36. Howell, M., A. Shirvan, Y. Stern-Bach, S. Steiner-Mordoch, J.E. Strasser, G.E. Dean, and S. Schuldiner. 1994. Cloning and functional expression of a tetrabenazine sensitive vesicular monoamine transporter from bovine chromaffin granules. FEBS Lett. 338: 16.
37. Jahn, R. and T.C. Sudhof. 1994. Synaptic vesicles and exocytosis. Annu. Rev. Neurosci. 17: 219.
38. Javitch, J., R. D'Amato, J. Nye, and J. Javitch. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. 82: 2173.
39. Jenner, P., D.T. Dexter, J. Sian, A.H. Schapira, and C.D. Marsden. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32: (suppl) 82.
40. Johannessen, J.N., C.C. Chiueh, R.S. Burns, and S.P. Markey. 1985. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36: 219.
41. Johnson, R.G. 1988. Accumulation of biological amines into chromaffin granules: A model for hormone and neurotransmitter transport. Physiol. Rev. 68: 232.
42. Kalivas, P.W. and P. Duffy. 1993. Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. J. Neurosci. 13: 276.
43. Kaneko, M., A. Yamaguchi, and T. Sawai. 1985. Energetics of tetracycline efflux system encoded by Tn10 in Escherichia coli. FEBS Lett. 193: 194.
44. Kelly, R.B. 1991. Secretory granule and synaptic vesicle formation. Curr. Opin. Cell Biol. 3: 654.
45. _. 1993. Storage and release of neurotransmitters. Cell 72: 43.
46. Kish, S.J., L.M. Distefano, S. Dozic, Y. Robitaille, A. Rajput, J.H.N. Deck, and O. Hornykiewicz. 1990. 3H-Vesamicol binding in human brain cholinergic deficiency disorders. Neuroscience Lett. 117: 347.
47. Krejci, E., B. Gasnier, D. Button, M.F. Isambert, C. Sagne, J. Gagnon, J. Massoulie, and J.P. Henry. 1993. Expression and regulation of the bovine vesicular monoamine transporter gene. FEBS Lett. 335: 27.
48. +) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem. Biophys. Res. Commun. 169: 123.
49. Kuliawat, R. and P. Arvan. 1992. Protein targeting via the "constitutive-like" secretory pathway in isolated pancreatic islets: Passive sorting in the immature granule component. J. Cell Biol. 118: 521.
50. _. 1994. Distinct molecular mechanisms for protein sorting within immature secretory granules of pancreatic beta-cells. J. Cell Biol. 126: 77.
51. Langston, J.W., P. Ballard, J.W. Tetrud, and I. Irwin. 1983. Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 219: 979.
52. Langston, J.W., I. Irwin, E.G. Langston, and L.S. Forno. 1984. Pargyline prevents MPTP-induced Parkinsonism in primates. Science 225: 1480.
53. Lesch, K.P., J. Gross, B.L. Wolozin, E. Franzek, D. Bengel, P. Riederer, and D.L. Murphy. 1994. Direct sequencing of the reserpine-sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic depressive illness. Psychiatr. Genet 4: 153.
54. Liu, Y. and R.H. Edwards. 1996. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. (in press).
55. +. Proc. Natl. Acad. Sci. 89: 9074.
56. Liu, Y., E.S. Schweitzer, M.J. Nirenberg, V.M. Pickel, C.J. Evans, and R.H. Edwards. 1994. Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells. J. Cell Biol. 127: 1419.
57. + toxicity encodes a vesicular amine transporter. Cell 70: 539.
58. Maron, R., Y. Stern, B.I. Kanner, and S. Schuldiner. 1983. Functional asymmetry of the amine transporter from chromaffin granules. J. Biol. Chem. 258: 11476.
59. Martin, T.F.J. 1994. The molecular machinery for fast and slow neurosecretion. Curr. Opin. Neurobiol. 4: 626.
60. Merickel, A. and R.H. Edwards. 1995. Transport of histamine by vesicular monoamine transporter-2. Neuropharmacology 34: 1543.
61. Merickel, A., P. Rosandich, D. Peter, and R.H. Edwards. 1995. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J. Biol. Chem. 270: 25798.
62. Michel, P.P. and F. Hefti. 1990. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26: 428.
63. Mitchell, I.J., A.J. Cross, M. A. Sambrook, and A.R. Crossman. 1985. Sites of the neurotoxtc action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61: 195.
64. Nakanishi, N., S. Onozawa, R. Matsumoto, H. Hasegawa, and S. Yamada. 1995. Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells. FEBS Lett. 368: 411.
65. Neal, R.J. and K.F. Chater. 1987. Nucleotide sequence analysis reveals similarities between proteins determining methylenomycin A resistance in streptomyces and tetracycline resistance in eubacteria. Gene 58: 229.
66. Neyfakh, A.A., V.E. Bidnenko, and L.B. Chen. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: Similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. 88: 4781.
67. Nguyen, T.T., K. Postle, and K.P. Bertrand. 1983. Sequence homology between the tetracycline-resistance determinants of Tn10 and pBR322. Gene 25: 83.
68. Nicklas, W.J., I. Vyas, and R.E. Heikkila. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36: 2503.
69. Nirenberg, M.J. J. Chan, Y. Liu, R.H. Edwards, and V.M. Pichel. 1996. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: Potential sites for somatodendritic storage and release of dopamine. J. Neurosci. 16: 14135.
70. Nirenberg, M.J., Y. Liu, D. Peter, R.H. Edwards, and V.M. Pickel. 1995. The vesicular monoamine transporter-2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc. Natl. Acad. Sci. 92: 8773.
71. Parkinson's Study Group. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364.
72. _. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328: 176.
73. Peter, D., T. Vu, and R.H. Edwards. 1996. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. J. Biol. Chem. 271: 2979.
74. Peter, D., J. Jimenez, Y. Liu, J. Kim, and R.H. Edwards. 1994. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J. Biol. Chem. 269: 7231.
75. Peter, D., Y. Liu, C. Sternini, R. de Giorgio, N. Brecha, and R.H. Edwards. 1995. Differential expression of two vesicular monoamine transporters. J. Neurosci. 15: 6179.
76. Peter, D., J.P. Finn, I. Klisak, Y. Liu, T. Kojis, C. Heinzmann, A. Roghani, R.S. Sparkes, and R.H. Edwards. 1993. Chromosomal localization of the human vesicular amine transporter genes. Genomics 18: 720.
77. Przedborski, S., V. Kostic, V. Jackson-Lewis, A.B. Naini, S. Simonetti, S. Fahn, E. Carlson, C.J. Epstein, and J.L. Cadet. 1992. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12: 1658.
78. Ramsay, R.R. and T. P. Singer. 1986. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261: 7585.
79. +) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 56: 1184.
80. Regnier-Vigouroux, A., S.A. Tooze, and W.B. Huttner. 1991. Newly synthesized synaptophysin is transported to synaptic-like microvesicles via constitutive secretory vesicles and the plasma membrane. EMBO J. 10: 3589.
81. Roghani, A., J. Feldman, S.A. Kohan, A. Shirzadi, C.B. Gundersen, N. Brecha, and R.H. Edwards. 1994. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc. Natl. Acad. Sci. 91: 10620.
82. Rosenberg, P.A. 1988. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8: 2887.
83. Ruberg, M., W. Mayo, A. Brice, C. Duyckaerts, J.J. Hauw, H. Simon, M. LeMoal, and Y. Agid. 1990. Choline acetyltransferase activity and 3H-vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions. Neuroscience 35: 327.
84. Rudnick, G. and S.C. Wall. 1992a. The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamin (MDMA)]: Serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. 89: 1817.
85. _. 1992b. p-Chloroamphetamine induces serotonin release through serotonin transporters. Biochemistry 31: 6710.
86. _. 1992c. Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol. Pharmacol. 43: 271.
87. Rudnick, G., S.S. Steiner-Mordoch, H. Fishkes, Y. Stern-Bach, and S. Schuldiner. 1990. Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter. Biochemistry 29: 603.
88. Ryan, T.A., H. Reuter, B. Wendland, F.E. Schweizer, R.W. Tsien, and S.J. Smith. 1993. The kinetics of synaptic vesicle recycling measured at single presynaptic boutons. Neuron 11: 713.
89. Schapira, A., J. Cooper, D. Dexter, J. Clark, P. Jenner, and C.D. Marsden. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54: 823.
90. Scherman, D. and J.P. Henry. 1984. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol. Pharmacol. 25: 113.
91. Scherman, D., F. Darchen, C. Desnos, and J.P. Henry. 1988. 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine transport system of chromaffin granules. Eur. J. Pharmacol. 146: 359.
92. Schuldiner, S., Y. Liu, and R.H. Edwards. 1993a. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J. Biol. Chem. 268: 29.
93. Schuldiner, S., A. Shirvan, and M. Linial. 1995. Vesicular neurotransmitter transporters: From bacteria to humans. Physiol. Rev. 75: 369.
94. Schuldiner, S., S. Steiner-Mordoch, R. Yelin, S.C. Wall, and G. Rudnick. 1993b. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44: 1227.
95. Shirvan, A., O. Laskar, S. Steiner-Mordoch, and S. Schuldiner. 1994. Histidine-419 plays a role in energy coupling in the vesicular monoamine transporter from rat. FEBS Lett. 356: 145.
96. Shoffner, J.M., R.L. Watts, J.L. Juncos, A. Torroni, and D.C. Wallace. 1991. Mitochondrial oxidative phosphorylation in Parkinson's disease. Ann. Neurol. 30: 332.
97. Smith, A.D. 1972. Mechanisms involved in the release of noradrenaline from sympathetic nerve. Br. Med. Bull. 29: 123.
98. Steele, T.D., U.D. McCann, and G.A. Ricaurte. 1994. 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy): Pharmacology and toxicology in animals and humans. Addiction 89: 539.
99. Stem-Bach, Y., J.N. Keen, M. Bejerano, S. Steiner-Mordoch, M. Wallach, J.B. Findlay, and S. Schuldiner. 1992. Homology of a vesicular amine transporter to a gene conferring resistance to 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. 89: 9730.
100. Strader, C.D., M.R. Candelore, W.S. Hill, I.S. Sigal, and R.A.F. Dixon. 1989. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J. Biol. Chem. 264: 13572.
101. Sulzer, D. and S. Rayport. 1990. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: A mechanism of action. Neuron 5: 797.
102. Sulzer, D., N.T. Maidment, and S. Rayport. 1993. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60: 527.
103. Surratt, C.K., A.M. Persico, X.-D. Yang, S.R. Edgar, G.S. Bird, A.L. Hawkins, C.A. Griffin, X. Li, E.W. Jabs, and G.R. Uhl. 1993. A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs. FEBS Lett. 318: 325.
104. Tanner, C.M. and J.W. Langston. 1990. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40: 17.
105. Thureson-Klein, A. 1983. Exocytosis from large and small dense cored vesicles in noradrenergic nerve terminals. Neuroscience 10: 245.
106. Tooze, J. and S.A. Tooze. 1986. Clathrin-coated vesicular transport of secretory proteins during the formation of ACTH-containing secretory granules in AtT20 cells. J. Cell Biol. 103: 839.
107. Tooze, S.A., E. Chanat, J. Tooze, and W.B. Huttner. 1993. Secretory granule formation. In Mechanisms of intracellular trafficking and processing of proproteins, p. 157. CRC Press, Boca Raton, Florida.
108. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414.
109. Varoqui, H., M.-F. Diebler, F.-M. Meunier, J.B. Rand, T.B. Usdin, T.I. Bonner, L.E. Eiden, and J.D. Erickson. 1994. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans. FEBS Lett. 342: 97.
110. Vingerhoets, F.J., B.J. Snow, J.W. Tetrud, J.W. Langston, M. Schulzer, and D.B. Calne. 1994. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. 36: 765.
111. Wall, S.C., H. Gu, and G. Rudnick. 1995. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: Amphetamine specificity for inhibition and efflux. Mol. Pharmacol. 47: 544.
112. Weaver, J.H. and J.D. Deupree. 1982. Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. Eur. J. Pharmacol. 80: 437.
113. Westlund, K.N., R.M. Denney, R.M. Rose, and C.W. Abell. 1988. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25: 439.